Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial

Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial

(2016) Michael Untch et al.   LANCET ONCOLOGY

Caveolin and cavin family members: Dual roles in cancer

(2014) Reshu Gupta et al.   BIOCHIMIE

Higher rate of skin rash in a phase II trial with weekly nanoparticle albumin-bound paclitaxel and cisplatin combination in Chinese breast cancer patients

(2013) Li Chen Tang et al.   BMC CANCER

Breast cancer statistics, 2011

(2011) Carol DeSantis et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Stromal Caveolin-1 Expression in Breast Carcinoma. Correlation with Early Tumor Recurrence and Clinical Outcome

(2011) Saba Mohamed El-Gendi et al.   PATHOLOGY & ONCOLOGY RESEARCH

Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

(2010) Christopher Lobo et al.   BREAST CANCER RESEARCH AND TREATMENT

Significantly Longer Progression-Free Survival Withnab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer

(2009) William J. Gradishar et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane(R)) in combination with gemcitabine in patients with metastatic breast cancer (N0531)

(2008) V. Roy et al.   ANNALS OF ONCOLOGY

Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype

(2008) S E Elsheikh et al.   BRITISH JOURNAL OF CANCER

Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment

(2008) Kathy S. Albain et al.   JOURNAL OF CLINICAL ONCOLOGY